Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Ascending Oral Doses of SUL-238 in Healthy Subjects

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Ascending Oral Doses of SUL-238 in Healthy Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SUL 238 (Primary)
  • Indications Acute kidney injury; Alzheimer's disease; Chronic heart failure; Chronic obstructive pulmonary disease; Neurodegenerative disorders; Pulmonary arterial hypertension; Sepsis
  • Focus Adverse reactions; First in man
  • Acronyms GN-001

Most Recent Events

  • 08 Nov 2024 Number of treatment arms are increased from 5 to 7 by the addition of 2 new arms for Active Comparator and Placebo Comparator assessing the food effects.
  • 08 Nov 2024 Planned number of patients changed from 69 to 83.
  • 04 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top